A pentapeptide monocyte locomotion inhibitory factor protects brain ischemia injury by targeting the eEF1A1/endothelial nitric oxide synthase pathway

Stroke

Volumn 43, Issue 10, 2012, Pages 2764-2773

  Zhang, Yuefan ^a   Chen, Jun ^a   Li, Fan ^a   Li, Dong ^a   Xiong, Qinhui ^a   Lin, Yang ^a   Zhang, Dazhi ^a   Wang, Xiao Fan ^b   Yang, Pengyuan ^a,b   Rui, Yao Cheng ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

brain ischemia; EEF1A1; eNOS; monocyte locomotion inhibitory factor; monocyte locomotion inhibitory factorbrain ischemia; pentapeptide

Indexed keywords

BIOTIN; CELL ADHESION MOLECULE; EEF1A1 PROTEIN; ELONGATION FACTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MESSENGER RNA; MONOCYTE LOCOMOTION INHIBITORY FACTOR; NEUROPROTECTIVE AGENT; NITRIC OXIDE; PENTAPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN ISCHEMIA; BRAIN PROTECTION; BRAIN SIZE; CONTROLLED STUDY; ENZYME INHIBITION; GENE SILENCING; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MASS SPECTROMETRY; MICROVASCULAR ENDOTHELIAL CELL; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RAT; RNA STABILITY; SURVIVAL TIME;

ANIMALS; BRAIN INJURIES; BRAIN ISCHEMIA; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MODELS, ANIMAL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OLIGOPEPTIDES; PEPTIDE ELONGATION FACTOR 1; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84866731875     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.657908     Document Type: Article

References (40)

1. Towfighi A, Ovbiagele B, Saver JL. Therapeutic milestone: stroke declines from the second to the third leading organ-and disease-specific cause of death in the United States. Stroke. 2010;41:499-503.
2. Kinlay S. Changes in stroke epidemiology, prevention, and treatment. Circulation. 2011;124:e494-e496.
3. Woodruff TM, Thundyil J, Tang SC, Sobey CG, Taylor SM, Arumugam TV. Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Mol Neurodegener. 2011;6:11.
4. Lakhan SE, Kirchgessner A, Hofer M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med. 2009;7:97.
5. Del Rio D, Agnoli C, Pellegrini N, Krogh V, Brighenti F, Mazzeo T, et al. Total antioxidant capacity of the diet is associated with lower risk of ischemic stroke in a large Italian cohort. J Nutr. 2011;141:118-123.
6. Smedbakken L, Jensen JK, Hallen J, Atar D, Januzzi JL, Halvorsen B, et al. Activated leukocyte cell adhesion molecule and prognosis in acute ischemic stroke. Stroke. 2011;42:2453-2458.
7. Brea D, Sobrino T, Ramos-Cabrer P, Castillo J. Inflammatory and neuroimmunomodulatory changes in acute cerebral ischemia. Cerebrovasc Dis. 2009;27(suppl 1):48-64.
8. McColl BW, Allan SM, Rothwell NJ. Systemic infection, inflammation and acute ischemic stroke. Neuroscience. 2009;158:1049-1061.
9. Todorcevic M, Kjaer MA, Djakovic N, Vegusdal A, Torstensen BE, Ruyter B. N-3 HUFAs affect fat deposition, susceptibility to oxidative stress, and apoptosis in Atlantic salmon visceral adipose tissue. Comp Biochem Physiol B Biochem Mol Biol. 2009;152:135-143.
10. Kretschmer R, Collado ML, Pacheco MG, Salinas MC, Lopez-Osuna M, Lecuona M, et al. Inhibition of human monocyte locomotion by products of axenically grown E. histolytica. Parasite Immunol. 1985;7:527-543. (Pubitemid 16256169)
11. Godina-Gonzalez S, Furuzawa-Carballeda J, Utrera-Barillas D, Alcocer-Varela J, Teran LM, Vazquez-del Mercado M, et al. Amebic monocyte locomotion inhibitory factor peptide ameliorates inflammation in cia mouse model by downregulation of cell adhesion, inflammation/chemotaxis, and matrix metalloproteinases genes. Inflamm Res. 2010;59: 1041-1051.
12. Velazquez JR. The monocyte locomotion inhibitory factor an antiinflammatory peptide; therapeutics originating from amebic abscess of the liver. Recent Pat Endocr Metab Immune Drug Discov. 2011;5:7-12.
13. Silva-Garcia R, Estrada-Garcia I, Ramos-Payan R, Torres-Salazar A, Morales-Martinez ME, Arenas-Aranda D, et al. The effect of an antiinflammatory pentapeptide produced by Entamoeba histolytica on gene expression in the U-937 monocytic cell line. Inflamm Res. 2008;57: 145-150.
14. Rojas-Dotor S, Perez-Ramos J, Gimenez-Scherer JA, Blanco-Favela F, Rico-Rosillo G. Effect of the monocyte locomotion inhibitory factor (MLIF) produced by E. histolytica on cytokines and chemokine receptors in T CD4-lymphocytes. Biol Res. 2009;42:415-425.
15. Rico G, Leandro E, Rojas S, Gimenez J, Kretschmer R. The effect of the monocyte locomotion inhibitory factor (MLIF) produced by entamoeba histolytica upon nitric oxide production by human leukocytes. Arch Med Res. 2000;31:S90-S91.
16. Gimenez-Scherer JA, Arenas E, Diaz L, Rico G, Fernandez J, Kretschmer R. Effect of the monocyte locomotion inhibitory factor (MLIF) produced by entamoeba histolytica on the expression of cell adhesion molecules (CAMs) in the skin of guinea pigs. Arch Med Res. 2000;31:S92-S93.
17. Yang P, Rui Y, Zhang Y. Use of polypeptides micro-molecule in preparing medicine for preventing and treating ischemic cerebrovascular disease. 2008; Patent (China) ZL200810200610.0.
18. Yao J, Xu Y, Ji F, Wang C, Zhang Y, Ni J, et al. Protective effects of MLIF analogs on cerebral ischemia-reperfusion injury in rats. Peptides. 2011;32:1047-1054.
19. Mori T, Takahashi T, Shiyama T, Tanaka A, Hira N, Tanaka N, et al. An easy preparation of 'monolithic type' hydrophilic solid phase: capability for affinity resin to isolate target proteins. Bioorg Med Chem. 2006;14: 5549-5554. (Pubitemid 43994469)
20. Yan G, You B, Chen SP, Liao JK, Sun J. Tumor necrosis factor-alpha downregulates endothelial nitric oxide synthase mRNA stability via translation elongation factor 1-alpha 1. Circ Res. 2008;103:591-597.
21. Kretschmer RR, Castro EM, Rico G, Pacheco G, Noriega R, Arellano J. Further characterization of a human monocyte locomotion inhibitory factor produced by axenically grown Entamoeba histolytica. Parasitol Res. 1989;75:245-246. (Pubitemid 19048100)
22. Rojas-Dotor S, Rico G, Perez J, Velazquez J, Silva R, Morales E, et al. Cytokine expression in CD4(+) cells exposed to the monocyte locomotion inhibitory factor produced by Entamoeba histolytica. Parasitol Res. 2006;98:493-495.
23. Zhang RL, Chopp M, Li Y, Zaloga C, Jiang N, Jones ML, et al. Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat. Neurology. 1994;44:1747-1751. (Pubitemid 24286659)
24. Sessa WC. Molecular control of blood flow and angiogenesis: role of nitric oxide. J Thromb Haemost. 2009;7 Suppl 1:35-37.
25. Huang PL. eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab. 2009;20:295-302.
26. Bhanoori M. Endothelial nitric oxide synthase (eNOS) variants in cardiovascular disease: pharmacogenomic implications. Indian J Med Res. 2011;133:464-466.
27. Triggle CR, Ding H. A review of endothelial dysfunction in diabetes: a focus on the contribution of a dysfunctional eNOS. J Am Soc Hypertens. 2010;4:102-115.
28. Garcia-Cardena G, Fan R, Shah V, Sorrentino R, Cirino G, Papapetropoulos A, Sessa WC. Dynamic activation of endothelial nitric oxide synthase by HSP90. Nature. 1998;392:821-824. (Pubitemid 28225323)
29. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007;87:315-424. (Pubitemid 46217686)
30. Kevil CG, Lefer DJ. Review focus on inorganic nitrite and nitrate in cardiovascular health and disease. Cardiovasc Res. 2011;89:489-491.
31. Sen N, Hara MR, Kornberg MD, Cascio MB, Bae BI, Shahani N, et al. Nitric oxide-induced nuclear GAPDH activates P300/CBP and mediates apoptosis. Nat Cell Biol. 2008;10:866-873. (Pubitemid 351934066)
32. Duranski MR, Elrod JW, Calvert JW, Bryan NS, Feelisch M, Lefer DJ. Genetic overexpression of eNOS attenuates hepatic ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2006;291: H2980-H2986. (Pubitemid 44904099)
33. Toda N, Ayajiki K, Okamura T. Cerebral blood flow regulation by nitric oxide in neurological disorders. Can J Physiol Pharmacol. 2009;87: 581-594.
34. Toda N, Ayajiki K, Okamura T. Cerebral blood flow regulation by nitric oxide: recent advances. Pharmacol Rev. 2009;61:62-97.
35. Khan M, Jatana M, Elango C, Paintlia AS, Singh AK, Singh I. Cerebrovascular protection by various nitric oxide donors in rats after experimental stroke. Nitric Oxide. 2006;15:114-124. (Pubitemid 44175884)
36. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol. 2007;184:53-68. (Pubitemid 46365991)
37. Fleming I. Molecular mechanisms underlying the activation of eNOS. Pflugers Arch. 2010;459:793-806.
38. Sawada N, Liao JK. Targeting eNOS and beyond: emerging heterogeneity of the role of endothelial rho proteins in stroke protection. Expert Rev Neurother. 2009;9:1171-1186.
39. Balligand JL, Feron O, Dessy C. eNOS activation by physical forces: from short-term regulation of contraction to chronic remodeling of cardiovascular tissues. Physiol Rev. 2009;89:481-534.
40. Kosmidou I, Moore JP, Weber M, Searles CD. Statin treatment and 3-polyadenylation of eNOS mRNA. Arterioscler Thromb Vasc Biol. 2007; 27:2642-2649. (Pubitemid 350158917)